Ovarian/Fallopian/Peritoneal

Relapsed or Refractory intolerant to standard care

- CCT5040
  - Phase I Open Label Dose Escalation Study of CRX100 in Advanced Solid Tumors
    - PI: Dorigo
    - BioEclipse Therapeutics
      - 1st Priority

Newly Diagnosed

- Diagnostic

- GYN0VA0042
  - BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions
    - PI: Lutz
    - Sponsor: Bracco Diagnostics

- GYN0VA0053
  - Phase III AVB-56-500 in Combination with Paclitaxel in Platinum-Resistant Recurrent Ovarian Cancer
    - PI: Diver
    - Pending

- VAR0211
  - Phase I/II MORAb-202 FolateReceptor Alpha-Targeting Antibody-Drug Conjugate in Selected Tumor Types
    - PI: Berek
    - Pending

Recurrent

- Platinum Resistant
  - GYN0VA0054
    - Phase III Alpelisib (BYL719) in Combination w/ Olaparib vs Chemotherapy in Platinum-Resistant or Refractory Ovarian Cancers
      - PI: Diver
      - Sponsor: Novartis Pharmaceuticals Corporation

- Platinum Resistant or Refractory

High Risk

- GYN0VA0044
  - Exploratory Study to Determine Optimal Timing of BR55 Contrast Enhanced Ultrasound of the Ovaries
    - PI: Lutz
    - Bracco

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu